Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
The Phase 2b TYDAL-TIMI 78 study aims to enroll approximately 216 patients who will be randomized in a 3:1 ratio to receive MAR001 or placebo every four weeks for 24 weeks. Patients in the MAR001 arms will be randomized to receive 300mg, 450mg or 900mg. The primary endpoints will evaluate the percent change from baseline at week 12 in fasting TGs and fasting RC as compared with placebo. Safety and tolerability will be assessed, and secondary endpoints include changes in fasting very low-density lipoprotein cholesterol (VLDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C).
"Despite significant progress in managing cardiovascular risk, many patients continue to face elevated risk due to high levels of remnant cholesterol carried on triglyceride-rich lipoproteins. The TYDAL-TIMI 78 study offers an important opportunity to explore the therapeutic potential of MAR001, a genetically informed and promising approach to targeting ANGPTL4,' said Marc S. Sabatine, M.D., M.P.H., chairman of the thrombolysis in myocardial infarction (TIMI) study group and TYDAL study chair. 'By addressing a major unmet need with a novel mechanism, this trial could pave the way for a new class of therapies to reduce residual risk in patients with cardiometabolic disease. We're pleased to lead this important study and look forward to evaluating MAR001's impact on meaningful lipid parameters and overall cardiovascular health.'
'The initiation of the TYDAL study marks an important milestone for Marea and for patients at risk of atherosclerotic cardiovascular disease,' said Josh Lehrer, M.D., chief executive officer of Marea. 'MAR001 is a first-in-class, genetically validated investigational therapy with the potential to improve outcomes by reducing remnant cholesterol and triglycerides - two critical and under-addressed drivers of residual cardiovascular risk. We're advancing MAR001 into a Phase 2b trial and aim to generate data that could shift the treatment paradigm in cardiometabolic disease. MAR001 may offer precision therapy for patients with elevated residual risk despite control of traditional factors. We expect topline TYDAL results in mid-2026 and are energized to move this innovative therapy closer to the patient.'
About MAR001
MAR001 is a monoclonal antibody designed to block the activity of ANGPTL4. MAR001 binds with high affinity to the N-terminal coiled-coil domain of ANGPTL4. Given the enrichment in expression of ANGPTL4 in adipose tissue, MAR001 leads to augmented hydrolysis of triglyceride (TG) rich lipoproteins and optimal storage of TGs, and both nonclinical and clinical studies have demonstrated significant reductions in TG and remnant cholesterol (RC), the cholesterol carried on TG-rich lipoproteins. Substantial reductions in TG and RC are predicted to reduce atherosclerotic cardiovascular disease (ASCVD) risk.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for atherosclerotic cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
11 hours ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.
Time Business News
a day ago
- Time Business News
Next-Gen Bioremediation Technologies Revolutionize Environmental Cleanup
Bioremediation is the process of using living organisms, such as germs, fungi, or plants, to make the environment clean and safe, to break or neutralize pollutants from soil, water and air. The bioremediation market is increasing due to increasing environmental concerns, strict government rules on pollution control, increasing industrial waste and demand for environmentally friendly and cost -effective cleaning methods. Increased awareness about progress and sustainable practices in biotechnology is moving forward in areas such as oil and gas, agriculture and waste water treatment. Key Growth Drivers and Opportunities Increasing Environmental Concerns: Increasing environmental concerns are driving the growth of the bioremediation market as governments, industries, and communities seek sustainable and eco-friendly solutions to combat pollution. With increasing awareness about industrial waste, oil spread, and contaminated soil and harmful effects of water, the demand for natural and less aggressive cleaning methods is increasing. Bioremediation provides an effective, cost-efficient and environmentally safe option for traditional therapeutic techniques, causing widespread adoption and market expansion in areas. Challenges The bioremediation market faces limitations such as microbial or slow speed of plant-based cleanup processes, which may not be suitable for emergency or large-scale contamination. Effectiveness may be unexpectedly due to the presence of toxins that disrupt microbial activity such as temperature, pH, and toxins. Additionally, bioremediation is often limited to specific types of pollutants and may require a wider site monitoring. Using genetically modified organisms (GMOs) can cause regulatory approval and widely adopting public skepticism. Innovation and Expansion The New Glyphosate Bioremediation Solution Revealed by Ancient Organics In May 2023, PaleoPower will go on sale, according to Ancient Organics Bioscience, Inc., an agricultural technology firm that creates its own line of plant and soil probiotics. The only substance that is known to decompose glyphosate contamination in soil naturally is PaleoPower. A group of helpful microbes called PaleoPower breaks down glyphosate. The active component of Roundup and other popular glyphosate-based herbicides is glyphosate. PaleoPower decreased soil glyphosate levels by more than 80% during 90 days of treatment and by more than 90% within 180 days of application in controlled tests. An Innovative Approach to Address Acid Mine Drainage in Northeast Coal Mines IIT Guwahati Develops In June 2022, The Indian Institute of Technology Guwahati A study on the 'bioremediation' of Acid Mine Drainage (AMD) in Constructed Wetlands has been conducted by researchers using coal mines. This is the first research to show how constructed wetlands may be used to bioremediate AMD from the Northeastern Coalfields (NEC). The term 'acid mine drainage' describes the acidic wastewater produced by coal mines (or any polymetallic mine) that contains significant levels of iron, sulfate, and other hazardous heavy metals. This study addresses the long-term operational sustainability concerns that arise in constructed wetlands that receive AMD while offering an effective sustainable treatment method to reduce AMD contamination. To further comprehend the operation of several basic processes that co-occur in constructed wetlands, a biochemical mechanism has been established. Inventive Sparks, Expanding Markets Major development strategies for bioremediation companies include investing in advanced microbial and genetic technologies, expanding applications in industries such as agriculture, oil and gas and waste water, forming partnership with environmental agencies and focusing on permanent, low -cost solutions. Companies aim to increase operations through government cooperations and regulatory approval by increasing R&D for targeted and rapid therapeutic methods. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Business Wire
a day ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
